Agents such as infliximab (a TNF inhibitor), tocilizumab (an IL-6 receptor antagonist), and rituximab (a CD20 monoclonal antibody) have demonstrated efficacy in controlling systemic autoimmune conditions with otologic manifestations 46. Here, TNF is linked to Autoimmunity.